TuisA1LN34 • BVMF
add
Alnylam Pharmaceuticals Inc Bdr
Vorige sluiting
R$70,73
Dagwisseling
R$72,84 - R$73,15
Jaarwisseling
R$37,68 - R$85,44
Markkapitalisasie
33,46 mjd USD
Gemiddelde volume
33,00
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 593,17 m | 34,90% |
Bedryfskoste | 595,51 m | 26,63% |
Netto inkomste | -83,76 m | 39,24% |
Netto winsgrens | -14,12 | 54,96% |
Wins per aandeel | 0,06 | 107,79% |
EBITDA | -90,99 m | 11,59% |
Effektiewe belastingkoers | 56,81% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,69 mjd | 10,46% |
Totale bates | 4,24 mjd | 10,71% |
Totale aanspreeklikheid | 4,17 mjd | 3,02% |
Totale ekwiteit | 67,09 m | — |
Uitstaande aandele | 129,46 m | — |
Prys om te bespreek | 136,02 | — |
Opbrengs op bates | -6,23% | — |
Opbrengs op kapitaal | -9,44% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -83,76 m | 39,24% |
Kontant van bedrywe | -94,66 m | -217,71% |
Kontant van beleggings | -52,91 m | 78,01% |
Kontant van finansiering | 31,00 m | -20,98% |
Netto kontantverandering | -133,85 m | 39,25% |
Beskikbare kontantvloei | -110,30 m | -165,23% |
Meer oor
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Gestig
14 Jun. 2002
Webwerf
Werknemers
2 230
